Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden in connection with the investment round in Amra
Mandate

Vinge advises Industrifonden in connection with the investment round in Amra

January 24, 2017

Vinge has advised Industrifonden in connection with an investment round of USD 9 million for the digital health company Advanced MR Analytics AB (AMRA).

The investment round was led by Pfizer Venture Investments and VC Novo Seeds together with the existing investor Industrifonden.

AMRA has developed a method for measuring body fat and muscle mass using a magnetic camera. The company’s aim is to assess the risk of serious illness based upon the patient’s body profile. The investment round facilitates an international establishment and an expanded network among leading pharmaceutical companies.

Vinge’s team consisted of Johan Larsson and Johan Mattsson.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024